ArticleScience translational medicine2015
ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.
Article in Science translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 153 citations in OpenAlex.
- The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers.The Journal of clinical investigation · 2026Trial
- Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation.JCI insight · 2023Trial
- Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.Blood advances · 2018Trial
- Trial
- Interleukin-33 and its receptor: multifaceted roles and emerging therapeutic potential.Nature reviews. Immunology · 2026Review
- MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.medRxiv : the preprint server for health sciences · 2026Article
- Decoding TNF receptor superfamily control of CD4Cell communication and signaling : CCS · 2026Review
- Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.Blood immunology & cellular therapy · 2026Article
- Risk biomarkers of chronic GVHD in children aged 10 years or younger and children/adults older than 10 years.Blood advances · 2026Article
- Constitutively high levels of endogenous soluble ST2 inhibit food allergic responses in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Soluble ST2 as a biomarker for predicting severe adverse events among pediatric patients with Mycoplasma pneumoniae pneumonia.PloS one · 2026Article
- The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.Blood advances · 2025Article
- ST2/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche.Nature communications · 2025Article
- Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway.Nature communications · 2025Article
- Prediction and Prognostication of Acute Graft-Versus-Host Disease by MAGIC Biomarkers.American journal of hematology · 2025Review
- Soluble ST2 as a Predictive Biomarker for Acute Graft-Versus-Host Disease Post -Allogeneic Stem Cell Transplantation.Clinical transplantation · 2025Article
- Biochemical markers and emerging therapies for intestinal manifestation of graft-versus-host disease.Frontiers in immunology · 2025Review
- Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.Transplantation and cellular therapy · 2024Article
- Article
- The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.Blood advances · 2024Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
Graft-versus-host disease (GVHD) remains a devastating complication after allogeneic hematopoietic cell transplantation (HCT). We previously identified high plasma soluble suppression of tumorigenicity 2 (sST2) as a biomarker of the development of GVHD and death. sST2 sequesters interleukin-33 (IL-33), limiting its availability to T cells expressing membrane-bound ST2 (mST2) [T helper 2 (TH2) cells and ST2(+)FoxP3(+) regulatory T cells]. We report that blockade of sST2 in the peritransplant period with a neutralizing monoclonal antibody (anti-ST2 mAb) reduced GVHD severity and mortality. We identified intestinal stromal cells and T cells as major sources of sST2 during GVHD. ST2 blockade decreased systemic interferon-γ, IL-17, and IL-23 but increased IL-10 and IL-33 plasma levels. ST2 blockade also reduced sST2 production by IL-17-producing T cells while maintaining protective mST2-expressing T cells, increasing the frequency of intestinal myeloid-derived suppressor cells, and decreasing the frequency of intestinal CD103 dendritic cells. Finally, ST2 blockade preserved graft-versus-leukemia activity in a model of green fluorescent protein (GFP)-positive MLL-AF9 acute myeloid leukemia. Our findings suggest that ST2 is a therapeutic target for severe GVHD and that the ST2/IL-33 pathway could be investigated in other T cell-mediated immune disorders with loss of tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.